Sophoridine suppresses lenvatinib‐resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression

伦瓦提尼 癌症研究 MAPK/ERK通路 医学 肝细胞癌 细胞生长 索拉非尼 激酶 药理学 肿瘤科 生物 细胞生物学 遗传学
作者
Zhongwei Zhao,Dengke Zhang,Fazong Wu,Jianfei Tu,Jingjing Song,Min Xu,Jiansong Ji
出处
期刊:Journal of Cellular and Molecular Medicine [Wiley]
卷期号:25 (1): 549-560 被引量:66
标识
DOI:10.1111/jcmm.16108
摘要

Abstract Hepatocellular carcinoma (HCC) is one of the most lethal cancer types with insufficient approved therapies, among which lenvatinib is a newly approved multi‐targeted tyrosine kinase inhibitor for frontline advanced HCC treatment. However, resistance to lenvatinib has been reported in HCC treatment recently, which limits the clinical benefits of lenvatinib. This study aims to investigate the underlying mechanism of lenvatinib resistance and explore the potential drug to improve the treatment for lenvatinib‐resistant (LR) HCC. Here, we developed two human LR HCC cell lines by culturing with long‐term exposure to lenvatinib. Results showed that the vascular endothelial growth factor receptors (VEGFR)2 expression and its downstream RAS/MEK/ERK signalling were obviously up‐regulated in LR HCC cells, whereas the expression of VEGFR1, VEGFR3, FGFR1‐4 and PDGFRα/β showed no difference. Furthermore, ETS‐1 was identified to be responsible for VEGFR2 mediated lenvatinib resistance. The cell models were further used to explore the potential strategies for restoration of sensitivity of lenvatinib. Sophoridine, an alkaloid extraction, inhibited the proliferation, colony formation, cell migration and increased apoptosis of LR HCC cells. In vivo and in vitro results showed Sophoridine could further sensitize the therapeutic of lenvatinib against LR HCC. Mechanism studies revealed that Sophoridine decreased ETS‐1 expression to down‐regulate VEGFR2 expression along with downstream RAS/MEK/ERK axis in LR HCC cells. Hence, our study revealed that up‐regulated VEGFR2 expression could be a predicator of the resistance of lenvatinib treatment against HCC and provided a potential candidate to restore the sensitivity of lenvatinib for HCC treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
LJN.up发布了新的文献求助10
刚刚
GTY完成签到,获得积分10
1秒前
苹果星月发布了新的文献求助20
5秒前
无糖可乐完成签到,获得积分10
5秒前
Glllll完成签到 ,获得积分10
6秒前
传奇3的应助被张点心采纳,获得10
6秒前
慈蔼的人完成签到 ,获得积分10
7秒前
共享精神的应助被十七采纳,获得10
7秒前
谨慎笑阳完成签到,获得积分10
7秒前
小胡完成签到,获得积分10
8秒前
Running发布了新的文献求助10
8秒前
景琦完成签到,获得积分10
8秒前
29完成签到,获得积分10
8秒前
8秒前
10秒前
11秒前
XZJ完成签到,获得积分10
12秒前
heiehi完成签到,获得积分10
12秒前
12秒前
12秒前
搜集达人的应助被明前易拉罐采纳,获得10
13秒前
高山完成签到 ,获得积分10
14秒前
Tao完成签到 ,获得积分10
15秒前
Jaylou完成签到,获得积分0
15秒前
16秒前
充电宝的应助被MADAO采纳,获得30
16秒前
上官若男的应助被青小泥采纳,获得10
16秒前
xing发布了新的文献求助10
16秒前
万能图书馆的应助被左白易采纳,获得10
17秒前
OS完成签到 ,获得积分10
17秒前
17秒前
陈晓钱完成签到,获得积分10
19秒前
19秒前
20秒前
xiaoxia完成签到,获得积分10
20秒前
DUMPLINGS完成签到 ,获得积分10
21秒前
21秒前
hnu完成签到,获得积分20
21秒前
充电宝的应助被suzy采纳,获得10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571537
关于积分的说明 21818552
捐赠科研通 7778091
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479621